Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: A chromogenic in situ hybridization study of 182 patients

Lung Cancer

Volumn 61, Issue 3, 2008, Pages 328-339

  Chang, John Wen Cheng ^a   Liu, Hui Ping ^a   Hsieh, Meng Heng ^a   Fang, Yueh Fu ^a   Hsieh, Meng Shu ^a   Hsieh, Jia Juan ^a   Chiu, Yu Ting ^b   Tsai, Hsien Yu ^b   Chen, Yi Hsuan ^b   Chen, Ya Ting ^b   Hsu, Hui Yu ^b   Chen, Ying Tsong ^b   Tsai, Shih Feng ^b   Chen, Yi Rong ^b   Hsi, Bae Li ^b   Huang, Shiu Feng ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Chromogenic in situ hybridization; EGFR mutation; Gene copy number; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; DRUG SENSITIVITY; EXON; FEMALE; GENE MUTATION; GENE NUMBER; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR CELL; WILD TYPE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; FEMALE; GENE DOSAGE; GENES, ERBB-1; GENES, RAS; HUMANS; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 50849094202     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.01.009     Document Type: Article

References (39)

1. Bach P.B., and Ginsberg R.J. Epidemiology of lung cancer in Ginsberg RJ. Lung cancer (2002), BC Decker Inc. p. 1-3
2. Breathnach O.S., Freidlin B., Conley B., Green M.R., Johnson D.H., Gandara D.R., et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19 (2001) 1734-1742
3. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of premetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
4. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 (2001) 1038-1042
5. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
6. Arteaga C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29 Suppl. 14 (2002) 3-9
7. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21 (2003) 2237-2246
8. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
9. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
10. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
11. Kris M.G. How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care. Oncologist 10 Suppl. 2 (2005) 23-29
12. Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10 (2004) 8195-8203
13. Chou T.Y., Chiu C.H., Li L.H., Hsiao C.Y., Tzen C.Y., Chang K.T., et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11 (2005) 3750-3757
14. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 (2005) 2513-2520
15. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 (2005) 6829-6837
16. Han S.W., Kim T.Y., Hwang P.G., Jeong S., Kim J., Choi I.S., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23 (2005) 2493-2501
17. Kim K.S., Jeong J.Y., Kim Y.C., Na K.J., Kim Y.H., Ahn S.J., et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 11 (2005) 2244-2251
18. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24 (2006) 3340-3346
19. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
20. Hirsch F.R., Varella-Garcia M., McCoy J., West H., Xavier A.C., Gumerlock P., et al., Southwest Oncology Group. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 23 (2005) 6838-6845
21. Hirsch F.R., Varella-Garcia M., Bunn P.A., Franklin W.A., Dziadziuszko R., Thatcher N., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 5034-5042
22. Hirsch F.R., Varella-Garcia M., Cappuzzo F., McCoy J., Bemis L., Xavier A.C., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18 (2007) 752-760
23. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
24. Mitsudomi T., Kosaka T., and Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 11 (2006) 190-198
25. Sharma S.V., Bell D.W., Settleman J., and Haber D. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7 (2007) 169-181
26. Sharma S.V., Gajowniczek P., Way I.P., Lee D.Y., Jiang J., Yuza Y., et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10 (2006) 425-435
27. Olayioye M.A., Neve R.M., Lane H.A., and Hynes N.E. The erbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 (2000) 3159-3167
28. Pinkas-Kramarski R., Soussan L., Waterman H., Levkowitz G., Alroy I., Klapper L., et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15 (1996) 2452-2467
29. Hsieh M.H., Fang Y.F., Chang W.C., Kuo H.P., Lin S.Y., Liu H.P., et al. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer 53 (2006) 311-322
30. Tsai H.Y., Hsi B.L., Hung I.J., Yang C.P., Lin J.N., Chen J.C., et al. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections. Human Pathol 35 (2004) 1397-1403
31. Huang S.F., Hudson T.J., Renshaw A.A., Xiao S., and Fletcher J.A. Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer. Am J Pathol 149 (1996) 1565-1573
32. Huang S.F., Hsu H.C., and Fletcher J.A. Investigation of chromosomal aberrations on hepatocellular carcinoma by fluorescence in situ hybridization. Cancer Genet Cytogenet 111 (1999) 21-27
33. Huang S.F., Hsu H.C., Chen J.C., Chie W.C., and Lai P. Tetrasomy 6 and 6q14 deletion are associated with better survival in hepatocellular carcinomas-a fluorescence in situ hybridization study of 77 cases. Cancer Genet Cytogenet 144 (2003) 23-30
34. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
35. Bell D.W., Lynch T.J., Haserlat S.M., Harris P.L., Okimoto R.A., Brannigan B.W., et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23 (2005) 8081-8092
36. Hirsch F.R., Varella-Garcia M., Bunn P.A., Di Maria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21 (2003) 3798-3807
37. Dziadziuszko R., Witta S.E., Cappuzzo F., Park S., Tanaka K., Danenberg P.V., et al. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res 12 10 (2006 May 15) 3078-3084
38. Brodeur G.M., Hayes F.A., Green A.A., Casper J.T., Wasson J., Wallach S., et al. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res 47 (1987) 4248-4253
39. Tokumo M., Toyooka S., Ichihara S., Ohashi K., Tsukuda K., Ichimura K., et al. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer 53 (2006) 117-121